FDA To Rescind A 510(k): Rare Action Targets ReGen's Menaflex Device
This article was originally published in The Pink Sheet Daily
Executive Summary
The formal rescission process, including the option for ReGen to request a regulatory hearing, will proceed after FDA staffers have met with the manufacturer to discuss an appropriate marketing pathway for the device.